Literature DB >> 857645

Variation among commercial activated partial thromboplastin time reagents in response to heparin.

G A Shapiro, S W Huntzinger, J E Wilson.   

Abstract

The activated partial thromboplastin time (APTT) has been advocated for monitoring heparin effect. This study was designed to determine the in vitro sensitivity to heparin of commercially available APTT reagents. Heparin was added in increasing concentrations to pooled citrated plasma. Fibrometer APTT determinations were performed at each concentration using General Diagnostics, Ortho, Dade, Hyland, and BBL reagents. A tilt-tube kaolin-activated partial thromboplastin time was also tested using a Sigma partial thromboplastin prepared by the method of Bell and Alton. The General Diagnostics, Sigma, and Ortho reagents displayed linear heparin sensitivity; the General Diagnostics APTT was prolonged 1 1/2-2 1/2 times in a plasma heparin range that prolonged a modified in-vitro Lee-White clotting times 2-3 times. The other reagents were either insensitive, too sensitive, or nonlinear in heparin response. Thus, commercial reagents vary widely in their in-vitro sensitivity to heparin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 857645     DOI: 10.1093/ajcp/67.5.477

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?

Authors:  Florin Ioan Anton; Paul Adrian Rus; Natalia Hagau
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-08-11

3.  The effect of oral anticoagulant therapy on APTT results from a bedside coagulation monitor.

Authors:  M J Ray; P A Carroll; S J Just; G A Hawson; J H Bett
Journal:  J Clin Monit       Date:  1994-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.